CA-WIND-RIVER
26.4.2022 12:02:24 CEST | Business Wire | Press release
Wind River® , a global leader in delivering software for intelligent systems, today announced it has been selected by BAE Systems to support technology demonstration work as part of the Tempest future combat air system program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005579/en/
“We are honored be working with BAE Systems,” said Avijit Sinha, chief product officer, Wind River. “The selection of our industry-leading technology demonstrates continuing Wind River leadership in safety-critical real-time software solutions for avionics.”
Wind River software is in use by more than 360 customers over 600 safety programs in more than 100 civilian, military, and space systems, delivering innovative technology that solves real business problems.
BAE Systems will be using the VxWorks 653 platform, a part of Wind River Studio , and associated DO-178C DAL B safety certification evidence packages, and AdaCore GNAT Pro Assurance as part of ongoing technology demonstration project work in support of the program. Wind River Studio is a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems.
The aerospace and defense market has high urgency to build the most complete intelligent systems, according to recent research. True compute on the far edge and the ability to emulate and simulate in real time are two of the most important intelligent systems characteristics for future success. In this industry, the ability to make accurate, quick decisions in high-risk scenarios is critical, and artificial intelligence is becoming an increasingly important investment.1
Team Tempest is a co-funded technology initiative launched by the Royal Air Force Rapid Capabilities Office and U.K. industry partners with the aim of advancing combat air technology. BAE Systems is one of the founding members of Team Tempest.
The Tempest future combat air system will incorporate advanced technical capabilities including AI, which creates opportunities such as the ability to fly manned or unmanned or to use swarming technology to control drones. Tempest is currently in the concept and assessment phase. Initial operating capability is expected in the mid-2030s.
Leveraging a safety-critical platform with COTS safety certification packages can reduce technical program risk. Proven in the most challenging safety-critical applications, VxWorks 653 makes it easier and more cost-effective for technology suppliers to meet the stringent safety certification requirements of EN 50128, IEC 61508, ISO 26262, DO-178C, and ED-12C.
About Wind River
Wind River is a global leader in delivering software for intelligent systems. The company’s technology has been powering the safest, most secure devices in the world since 1981 and is found in billions of products. Wind River offers a comprehensive portfolio, supported by world-class global professional services and support and a broad partner ecosystem. Wind River software and expertise are accelerating digital transformation of mission-critical intelligent systems that will increasingly demand greater compute and AI capabilities while delivering the highest levels of security, safety, and reliability. To learn more, visit Wind River at www.windriver.com .
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005579/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
